Bone Biologics launches $2M public offering


Bone Biologics, a company focused on spine fusion products, recently announced a $2 million public offering.

The public offering includes 781,251 shares of its common stock for $2.56 per share, according to a March 4 news release.

The company said it plans to use proceeds from the offering to support clinical trials, its patent portfolio and general corporate purposes, as well as for working capital.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers